Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page
- Check2 days agoChange DetectedMinor update to the Study Record dates/text; core study content such as eligibility criteria, endpoints, and treatment arms remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check9 days agoNo Change Detected
- Check31 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check38 days agoChange DetectedPage now adds extensive immune-related terminology and a version upgrade to v3.1.0; the previous v3.0.2 revision is removed.SummaryDifference0.7%

- Check52 days agoChange DetectedThe page now shows Revision v3.0.2 and new September 2025 dates, while older dates and the previous Revision v3.0.1 have been removed.SummaryDifference0.3%

- Check59 days agoChange DetectedThe page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous update information has been removed.SummaryDifference0.1%

- Check67 days agoChange DetectedThe web page has been updated to include a new facility name and location details, along with a range of medical and diagnostic techniques, while removing outdated location information and certain medical terms.SummaryDifference2%

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.